Spotlight Innovation Appoints Dr. Geoffrey Laff as Vice President of Scientific Strategy

WEST DES MOINES, IA--(Marketwired - Jul 14, 2016) -  Spotlight Innovation Inc. (OTCQB: STLT) announced today that Geoffrey Laff, Ph.D., has joined the company in the new position of Vice President of Scientific Strategy. Dr. Laff will oversee the development and implementation of Spotlight Innovation's scientific research and development strategy, assist in the exploration and analysis of new acquisition opportunities, and contribute to clinical management activities.

Dr. Laff is a life sciences industry veteran with nearly 20 years of experience in healthcare venture capital, public equity investment, biotechnology, drug development, market research, and medical communications. Specializing in oncology and immunology, he has advised leading pharmaceutical companies including Pfizer, Bristol-Myers Squibb, Sanofi and Boehringer Ingelheim.

After earning a B.S. in Biology and a Ph.D. in Molecular Cell Biology from Yale University, Dr. Laff was a postdoctoral research fellow at Harvard Medical School. While at Yale he received the Sterling Prize Fellowship and the Dwight Hall Humanitarian Service Award.

Of his new role as Spotlight Innovation's Vice President of Scientific Strategy, Dr. Laff said, "I am honored to join the Spotlight Innovation team. I share with my colleagues a commitment to making a difference in the lives of patients through identification and development of innovative platform technologies. Together, we look forward to bringing breakthrough therapies to market."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.